Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
0.0%
operating margin TTM
0.0%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -5.86 |
| peg ratio | -0.06 |
| price to book ratio | 0.51 |
| price to sales ratio | 0.00 |
| enterprise value multiple | -2.88 |
| price fair value | 0.51 |
profitability ratios | |
|---|---|
| gross profit margin | 0.0% |
| operating profit margin | 0.0% |
| pretax profit margin | 0.0% |
| net profit margin | 0.0% |
| return on assets | -7.38% |
| return on equity | -8.54% |
| return on capital employed | -10.23% |
liquidity ratio | |
|---|---|
| current ratio | 15.33 |
| quick ratio | 15.33 |
| cash ratio | 4.84 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 0.00 |
| receivables turnover | 0.00 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.12 |
| debt equity ratio | 0.14 |
| long term debt to capitalization | 0.11 |
| total debt to capitalization | 0.12 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -0.78 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.76 |
| cash per share | 7.07 |
| operating cash flow per share | -0.75 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -0.78 |
| short term coverage ratios | -5.35 |
| capital expenditure coverage ratio | -63.02 |
Frequently Asked Questions
When was the last time Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) reported earnings?
Neoleukin Therapeutics, Inc. (NLTX) published its most recent earnings results on 30-09-2023.
What is Neoleukin Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)'s trailing twelve months ROE is -8.54%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Neoleukin Therapeutics, Inc. (NLTX) currently has a ROA of -7.38%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did NLTX's net profit margin stand at?
NLTX reported a profit margin of 0.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is NLTX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 15.33 in the most recent quarter. The quick ratio stood at 15.33, with a Debt/Eq ratio of 0.14.